Cargando…
The Law and Ethics of Switching from Biologic to Biosimilar in Canada
Governments and financial institutions in several jurisdictions are planning or implementing nonmedical/‘forced’ switches by cutting drug coverage for reference biologics and funding only less expensive biosimilars. Switches raise numerous ethical and legal challenges, as the drugs are framed as not...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465550/ https://www.ncbi.nlm.nih.gov/pubmed/32905067 http://dx.doi.org/10.1093/jcag/gwz043 |